A dual-target therapy known as HSK39004 is set to enter the competitive global market for Chronic Obstructive Pulmonary Disease (COPD) treatment. This innovative product signifies a focus on international capabilities and advancement. The announcement was made by Haisco Pharmaceutical Group Co., Ltd. on January 9, 2026. The company, identified by Ticker Code 002653, aims to make a significant impact in the field, showcasing their dedication to addressing respiratory issues on a global scale.